Tirzepatide Once Weekly for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. CONCLUSIONS: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many patients treated with GLP-1RAs achieve clinically meaningful weight loss while simultaneously demonstrating improvements in cardiometabolic health.45,46”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [46]
In the citing paper
“with two articles presenting LM outcomes in only a subset of participants from the parent trial (6, 7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Indeed, clinical trials demonstrate substantial weight loss achievable with GLP1Ra-based therapy, ranging from 12-15% over a one-year period for semaglutide (6), to weight losses rivaling what is seen with bariatric surgery for tirzepatide (7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Across body weight and composition outcomes, the greatest magnitude of weight loss was observed in the SURMOUNT (7) and STEP (6) trials, respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“However, the magnitude of the treatment effect on total body mass was nearly two times greater in trials using GLP1Ra-based therapies at dosages indicated primarily for chronic weight management (6, 7, 18, 21, 24) as compared to trials using dosages indicated primarily for diabetes management (17, 19, 20, 22): −10.2 kg (−16.3, −3.9) versus −5.5 kg (−8.7, −2.1), respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
174 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationObesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
Di Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationObesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Self-citationRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Cited by
Items 1,601–1,700 of 3,704
Martin, M. Y., & Rogers, R. J. (2024) · Annals of Behavioral Medicine · doi:10.1093/abm/kaae022 · Cited by 5
Genetics, pharmacotherapy, and dietary interventions in childhood obesity
Son, J. E. (2024) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.3389/jpps.2024.12861 · Cited by 15
Phenotyping of Obesity Treatment Candidates: A Narrative Review
Dagan, S. S., Refaeli, R., & Buch, A. (2024) · Current Obesity Reports · doi:10.1007/s13679-024-00576-x · Cited by 8
“In the SUR-MOUNT-1 trial aimed to evaluate tirzepatide once weekly in different dosages for weight management among 2,539 participants, of them 67.5% women with a mean age and BMI of 44.9 years and 38 kg/m 2 , the mean WC at baseline was 114.1 ± 15.2 cm [53].”
InfluentialA New Drug for Obesity: Tirzepatide
Sidhu, J. K., & Singh, S. (2024) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/0118715303319530240703111013 · Cited by 5
Kelly, A. S., Bahlke, M., Baker, J. L., de Beaufort, C. E., Belin, R. M., Fonseca, H., Hale, P. M., Holm, J., Hsia, D. S., Jastreboff, A. M., et al. (2024) · Pediatric Obesity · doi:10.1111/ijpo.13161 · Cited by 6
“5,32,33 Roundtable experts recommended that protocols should not be overly prescriptive about weight/BMI-based decision rules other than in extreme cases where a participant moves, or has a high potential of moving, into the underweight category.”
Self-citationCarlsson, L. M. S., Carlsson, B., Jacobson, P., Andersson‐Assarsson, J. C., Karlsson, C., Kristensson, F. M., Ahlin, S., Näslund, I., Karason, K., Svensson, P., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16010 · Cited by 6
“Consequently, it is tempting to speculate that a few years of treatment with recently developed potent weight loss medications 28,29 may delay diabetes onset and prolong life in individuals with obesity.”
Hathorn, B., Haykowsky, M. J., Almandoz, J. P., Pandey, A., Sarma, S., Hearon, C. M., Babb, T. G., Balmain, B. N., Fu, Q., Zaha, V. G., et al. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.03.015 · Cited by 9
Management of Adult Obstructive Sleep Apnoea: Many Questions, Not Enough Answers!
Stanczyk, M., McNicholas, W. T., Pevernagie, D., Riha, R. L., & Ryan, S. (2025) · Journal of Sleep Research · doi:10.1111/jsr.70047 · Cited by 7
Tackling the complexity of obesity in the US through adaptation of public health strategies
Ard, J. D., Huett-Garcia, A., & Bildner, M. E. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1477401 · Cited by 6
Hansrivijit, P., Ortega-Montiel, J., Wexler, D. J., Patorno, E., & Paik, J. M. (2025) · Kidney Medicine · doi:10.1016/j.xkme.2025.101013 · Cited by 6
“3-5 The effects of tir-zepatide on weight management were then further demonstrated in the SURMOUNT series trials, 6,7 which led to the FDA approval of tirzepatide for weight loss in November 2023 for adults with obesity, overweight, and obesity-related complications.”
López, G. P. (2025) · Medicina Clínica · doi:10.1016/j.medcli.2025.107122 · Cited by 5
Jiménez-Martí, E., Hurtado-Genovés, G., Aguilar-Ballester, M., Martínez‐Hervás, S., & Navarro, H. G. (2022) · Nutrients · doi:10.3390/nu14183775 · Cited by 7
“Until now, only SURMOUNT-1, whose primary outcomes are body reduction from the baseline and the percentage of participants achieving ≥5% body weight reduction by week 72, reported results that indicate an improvement in all the pre-specified cardiometabolic parameters [106].”
BackgroundBloomgarden, Z. T. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13434 · Cited by 5
Canagliflozin + metformin ER for the treatment of type 2 diabetes: the evidence to date
Tomlinson, B., & Li, Y. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2276180 · Cited by 6
“Tirzepatide is a dual agonist at both GLP1 and glucose-dependent insulinotropic polypeptide (GIP) and given subcutaneously once weekly it resulted in remarkable reductions in body weight in adults with obesity or overweight who did not have diabetes [31].”
BackgroundBassyouni, M., Mysara, M., Wohlers, I., Busch, H. S., Saber-Ayad, M. M., & El-Hadidi, M. S. (2023) · Scientific Reports · doi:10.1038/s41598-023-46844-z · Cited by 8
“In addition, it led to sustained remarkable reductions in body weight, according to the SURMOUNT-1 trial, NCT04184622 31 .”
Obesity and eating disorders: an interactive and complex coexistence
Grave, R. D. (2023) · IJEDO · doi:10.32044/ijedo.2023.04 · Cited by 5
A Robust Platform for the Molecular Design of Potent, Protease-Stable, Long-Acting GIP Analogues
Sicinski, K. M., Sürmeli, D., Du, J., Raman, V. S., Montanari, V., Lee, M., Harwood, B. N., Kopin, A. S., Beinborn, M., & Kumar, K. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00111 · Cited by 7
Pharmacologic treatment of obesity
Jung, H. N., & Jung, C. H. (2022) · Journal of Korean Medical Association · doi:10.5124/jkma.2022.65.7.408 · Cited by 5
Yoshiji, S., Lu, T., Butler‐Laporte, G., Carrasco-Zanini, J., Chen, Y., Liang, K. Y. H., Willett, J., Su, C., Wang, S., Adra, D., et al. (2023) · medRxiv · doi:10.1101/2023.04.19.23288706 · Cited by 5
Eisenberg, D., Shikora, S. A., & Kothari, S. N. (2023) · Obesity Surgery · doi:10.1007/s11695-023-06667-3 · Cited by 6
Tirzepatide inhibits tumor growth in mice with diet-induced obesityPreprint
Huang, L., Zeng, J., Wang, Y., & Pollak, M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.22.546093 · Cited by 6
“In common with other incretin-based drugs, it is effective for treatment of type II diabetes (14-17), and leads to substantial weight loss in obese subjects with or without T2D (18).”
An RNA-seq atlas of mouse brain areas during fasting and diet-induced obesity
Todorov, P. V., Klein, A. B., Egerod, K. L., Clemmensen, C., & Pers, T. H. (2024) · Scientific Data · doi:10.1038/s41597-023-02888-4 · Cited by 5
“Despite recent successes in treatment options for individuals living with obesity 1–3 , the condition continues to burden millions of individuals worldwide 4,5 .”
BackgroundFirst in class, best in class or a wild card: who will dominate the anti-obesity medication market?
Collins, E., Beattie, A., Ramagopalan, S. V., & Pearson‐Stuttard, J. (2024) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2024-0044 · Cited by 6
Rodriguez, P. J., Zhang, V., Gratzl, S., Do, D., Cartwright, B. M. G., Baker, C., Gluckman, T. J., Stucky, N. L., & Emanuel, E. J. (2024) · medRxiv · doi:10.1101/2024.07.26.24311058 · Cited by 5
Srivastava, G., Campbell, S. L., Hill, C. R., Stanley, T. L., Lawson, E. A., Apovian, C. M., Almandoz, J. P., Leggio, L., Lakdawalla, D. N., Dar, M., et al. (2025) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.06.015 · Cited by 5
“The ef fi cacy of these medications ranges up to 22.5% weight loss, with effects of novel medications like tirzepatide and semaglutide approaching outcomes comparable to surgical weight-loss procedures [3,4].”
InfluentialGlass, J., Carter, S., Artime, E., Higgins, V., Harrison, L., Leith, A., Lau, D. C. W., Patton, I. T., & Kuk, J. L. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100171 · Cited by 8
“In addition, the study was conducted prior to the broad uptake of newer generation OMMs such as semaglutide and tirzepatide, which have demonstrated substantial and sustained weight loss in PwO [27,28].”
Managing Diabetes in Older Adults: Current Approaches in Long-Term Care Facilities
Idrees, T., Castro-Revoredo, I., KANTIPUDI, S. L., & Umpierrez, G. E. (2025) · Current Diabetes Reports · doi:10.1007/s11892-025-01583-5 · Cited by 6
“For older adults in LTCFs treated with potent GLP-1 receptor agonists such as semaglutide and tirzepa-tide [81, 82], constant weight monitoring and oral intake should be ensured.”
The Goldilocks for chronic weight management—Balancing quantity with quality of weight loss
Henriksen, K., Chakravarthy, M. V., Bager, C. L., Larsen, A. T., Mohamed, K. E., & Karsdal, M. A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16379 · Cited by 4
“…this loss is not exclusively fat mass loss and includes some lean mass (approximately fourfold the loss in the placebo group), the weight-adjusted response is positive for lean mass. 11 In addition to its robust weight loss efficacy, it also possesses an extremely potent glu-coregulatory activity.”
Strategies for the Secondary Prevention of Atherosclerotic Cardiovascular Disease
Hurwitz, M., Agboola, O. J., Gami, A., Williams, M. S., Virani, S. S., Sharma, G. V., & Patel, J. (2025) · US Cardiology Review · doi:10.15420/usc.2024.33 · Cited by 10
Tavares, A. C. M., Martins, M. Y. M., de Souza, G. F., Lima, E. M., Rocha, C. A., de Souza, L. C., Simões, J. M. L., ARAÚJO, N. O. D., & Cavalcante, M. B. (2025) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2025.104538 · Cited by 12
Deep Phenotyping of Obesity: Electronic Health Record–Based Temporal Modeling Study
Ruan, X., Lu, S., Wang, L., Wen, A., Murali, S. B., & Liu, H. (2025) · Journal of Medical Internet Research · doi:10.2196/70140 · Cited by 7
“For AOMs, even the most effective glucagon-like peptide-1 (GLP-1) drug Tirzepatide claimed 10% weight loss in only 69% participants after 1 year at a relatively safe dosage [18].”
Review of Blood Pressure Control in Vulnerable Older Adults: The Role of Frailty and Sarcopenia
Sarnaik, K. S., & Mirzai, S. (2025) · Journal of Vascular Diseases · doi:10.3390/jvd4020018 · Cited by 13
“Importantly, due to the increased use of glucagon-like peptide-1 receptor agonists (GLP1RAs) for applications such as weight loss observed over recent years [137], providers must be keenly aware regarding the potential for substantial muscle loss associated with GLP1RA use [138,139].”
Seuntjens, J., Gols, J. D., Davies, B. K., Looy, F. V., Stockmans, I., Moermans, K., Carmeliet, G., Matthys, C., Vangoitsenhoven, R., der Schueren, B. V., et al. (2025) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00010.2025 · Cited by 6
Short-Term Effects of Tirzepatide in Obese Adults: A Real-World Prospective Study
Adamidis, N., Desalermos, A. P., Papadopoulou, N., Adamidi, S., Koutrakos, T., Kyventidou, M., Georgakopoulou, V., & Adamidis, S. (2025) · Cureus · doi:10.7759/cureus.85970 · Cited by 11
“Clinical trials such as SURPASS and SURMOUNT have demonstrated that tirzepatide leads to reductions in body weight exceeding those achieved by selective GLP-1 receptor agonists, with a mean weight loss reaching up to 22.5% in individuals with obesity without diabetes [8,9].”
InfluentialBody composition during major incretin-based weight loss
Dirksen, C., & Madsbad, S. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00122-6 · Cited by 5
From BMI to Disease Diagnosis: What Clinical and Pre-clinical Obesity Mean for Surgeons
Rubino, F., Brown, W. A., Schauer, P. R., Pattou, F. N., & COHEN, R. V. (2025) · Obesity Surgery · doi:10.1007/s11695-025-08159-y · Cited by 6
“The rise of effective anti-obesity medications [23, 24] has caused apprehension among some surgeons [25], but in most fields, treatment spans a range of options tailored to the patient’s condition.”
From genes to care: the expanding therapeutic horizon in rare genetic obesities
Chalopin, S., Guillon, E., Faucher, P., Dubern, B., Clément, K., & Poitou, C. (2025) · Obesity and Endocrinology · doi:10.1093/obendo/wjaf007 · Cited by 4
Barazzoni, R., Monami, M., Buscemi, S., Busetto, L., Luca, M. D., Navarra, G., Ragghianti, B., Silverii, G. A., Belluzzi, A., Mannucci, E., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70204 · Cited by 7
Funamizu, N., Funamizu, N., & Hirose, T. (2025) · Medicine · doi:10.1097/md.0000000000045445 · Cited by 4
“[10] In our patient, CPAP telemonitoring documented persistently low device-derived residual AHI during therapy; combined with sustained weight loss and symptom improvement, this supported supervised discontinuation of CPAP.”
Ameer, F., Villacres, N. Y., Bustos, D., Shah, P., Appah, N., Luzaya, G. N., Corradi, F., Bakare, I. S., Trujillo, J. V., Mylavarapu, M., et al. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01770-x · Cited by 5
“Additionally, it delays gastric emptying, inhibits glucagon release, and reduces appetite, leading to more effective blood glucose control and a significant reduction in body weight [4, 5].”
Ching, L. M., Guirguis, C. A., & Tung, J. K. (2025) · JEADV Clinical Practice · doi:10.1002/jvc2.70208 · Cited by 4
Impact of Reducing Obesity in PCOS: Methods and Treatment Outcomes
Dzienny, A. C., & Seifer, D. B. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15110518 · Cited by 7
“Tirzepatide was found to contribute to 22.9% of weight loss after 1 year, with a plateau for weight loss achieved at 3 to 6 months, although this was maintained with ongoing medical therapy [33,94,95].”
InfluentialReal-world effects of incretin-based Obesity medications on body composition
Bhatti, R., Sadiya, A., Mussa, B. M., Khan, R., & Abusnana, S. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100229 · Cited by 7
“5 % and 20.9 % respectively at 72 weeks [18].”
InfluentialDemidova, T. Y., & Izmaylova, M. Y. (2025) · FOCUS Endocrinology · doi:10.62751/2713-0177-2025-6-3-03 · Cited by 8
Kamrul-Hasan, A. B. M., Chatterjee, S., Ashraf, H., Nagendra, L., Dutta, D., & Pappachan, J. M. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.11.010 · Cited by 5
Blood Pressure-Lowering Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists
Siddiqi, A. K., Khan, M. S., Kulkarni, A., Hall, M. E., Böhm, M., Díez, J., & Butler, J. (2025) · Current Hypertension Reports · doi:10.1007/s11906-025-01342-7 · Cited by 5
“Participants were randomized in a 1:1:1:1 ratio to receive once-weekly sub - cutaneous tirzepatide at doses of 5 mg, 10 mg, or 15 mg, or placebo over a 72-week period [ 71 ].”
A real-world study of tirzepatide for weight loss in adults without diabetes mellitus
Angelopoulos, N., Androulakis, I. P., Rizoulis, A. A., Boniakos, A., Fousteris, E., Mentzelopoulou, V., Petkova, V. B., Paparodis, R. D., Zianni, D., Florakis, D., et al. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01986-0 · Cited by 9
Cozma, D. C., Văcărescu, C., & Stoicescu, C. I. (2025) · Biomedicines · doi:10.3390/biomedicines13123079 · Cited by 6
“…(SURMOUNT and diabetes trials) show very large total weight losses with reductions in both fat and lean mass; some analyses note relative preservation of lean mass proportionally and reductions in intramuscular fat, which could favor muscle efficiency—but absolute lean-mass loss still occurs [3].”
Constantine, E. P., Enthoven, L. F., Kahan, R., Pflug, E. M., & Lauder, A. S. (2025) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-24-01505 · Cited by 7
Eckert, D. J. (2025) · Drugs · doi:10.1007/s40265-025-02268-9 · Cited by 7
“Weekly injectable agonists such as semaglutide [90] and tirzepatide [91] achieve weight loss of 15–25% in 1 year in non-diabetics and 10–15% in diabetics.”
Joy, B., Ramsamooj, A., Ibrahim, S., Wen, J., Hsu, N., & Frezza, E. (2026) · Endocrine · doi:10.1007/s12020-025-04494-3 · Cited by 13
Talay, L., Hom, J., Scott, T., & Ahuja, N. K. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70462 · Cited by 5
“14 The arrival of semaglutide and tirzepatide as effective weight-loss supplements has coincided with the rapid growth of digital health solutions.”
Luca, M. D., COHEN, R. V., Belluzzi, A., Navarra, G., Lorenzo, N. D., Petry, T. B. Z., Sbraccia, P., Busetto, L., Buscemi, S., Barazzoni, R., et al. (2026) · Obesity · doi:10.1002/oby.70083 · Cited by 5
The effect of GLP-1 receptor agonist and SGLT2 inhibitor on infection risk: network meta-analysis
Zeng, B.-S., Chen, J.-J., Hsu, C.-W., Hung, C.-M., Zeng, B., Suen, M., Yang, W.-C., Wang, H.-Y., Shiue, Y.-L., Su, K.-P., et al. (2026) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2026.01.014 · Cited by 8
Molecular engineering of designer diabetes therapeutics
DeWolf, E. L., Webber, B., & Webber, M. J. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114705 · Cited by 5
iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.70167 · Cited by 5
The Impact of Weight Loss on the Physiological Endotypes Associated With OSA
Beatty, C., Wong, A., Landry, S. A., Thomson, L. D. J., Collet, J., Odeke, V., Joosten, S. A., Playfair, J., Malhotra, A., Kee, K., et al. (2026) · CHEST Journal · doi:10.1016/j.chest.2026.02.003 · Cited by 6
“9, 10 In contrast, MBS is usually a once-off procedure.”
Micronutrient Deficiencies in the Era of Second-Generation Incretin-Based Therapies for Obesity
Koceva, A., Janež, A., Pečko, T., & Jensterle, M. (2026) · Nutrients · doi:10.3390/nu18040677 · Cited by 7
“Dual agonists generally produce greater weight loss [1,3], which may theoretically lead to larger reductions in energy intake and amplify intake-mediated micronutrient risk by more pronounced reductions in total food volume and dietary variety.”
InfluentialAlper, A., Peleg, G., Fagin, A., Shah, P. P., Chowdhury, I. Z., Gonzales, A., & FAILLACE, R. T. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-025-00270-4 · Cited by 7
“This magnitude of weight loss compares favorably with established injectable GLP-1 RAs and dual agonists [26].”
Seijas‐Amigo, J., Salgado‐Barreira, Á., Rodríguez‐Penas, D., Cardeso-Paredes, B., Ribeiro-Ferreiro, M., Rodríguez‐Mañero, M., & González-Juanatey, J. (2026) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-026-02099-y · Cited by 4
“Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as liraglutide and semaglutide, and more recently dual GLP-1/GIP agonists like tirzepatide, have demonstrated substantial weight loss and cardiometabolic benefit in randomized clinical trials [3, 4].”
Meyer, K., McVeigh, M., Chiara, A. N., Boss, K. C., Pomfret, T. C., Semmel, K., Bacon, R., Nicolas, D., Clements, K. M., Alper, C. J., et al. (2026) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2026.32.3.271 · Cited by 7
Stone, D., Playdon, M. C., Hursting, S. D., & Tan, A. C. (2026) · Obesity · doi:10.1002/oby.70176 · Cited by 7
Johnson, A. J., O’Sullivan, E. N., Valyasevi, P., Metras, B. N., Jang, S., Shields‐Cutler, R. R., Arlinghaus, K. R., Harindhanavudhi, T., & Teigen, L. M. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0219 · Cited by 11
Ciudin, A., Sapin, H., Fan, L., Dimitriadis, G. K., Zimner‐Rapuch, S., Curteis, T., Clark, L. J., Rubinstein, M., & Johansson, E. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03523-5 · Cited by 9
“…week 56 (SCALE Obesity and Pre‑ diabetes), week 68 (STEP 1 and STEP 8) and week 72 (SURMOUNT‑1)—were considered broadly comparable, as the treatments were designed to reach full efficacy in this time‑ frame, and given the plateau observed across weight reduction outcomes around week 52 [19, 36–40].”
Lempesis, I. G., & Dalamaga, Μ. (2026) · Metabolism Open · doi:10.1016/j.metop.2026.100463 · Cited by 8
Galindo, R. J., Gudzune, K. A., Look, M., Lee, C. J., Benabbad, I., Cao, D., Meng, Q., & Mojdami, D. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.3274 · Cited by 4
Albor, C., Anyiam, O., Boyle, L., Makaronidis, J., Tan, R. J. L., Iftikhar, S., Burzić, A., Lajeunesse‐Trempe, F., Stanley, M., Bhatti, A. I., et al. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00707-6 · Cited by 5
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging
Mavrych, V., Shypilova, I., & Bolgova, O. (2026) · Frontiers in Aging · doi:10.3389/fragi.2026.1790247 · Cited by 7
Oikonomou, E. K., Chan, K., Patel, P., Wahome, E., Dangas, K., Desai, R., Sobirov, I., Khera, R., Petersen, S. E., Pugliese, F., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.02.5116 · Cited by 12
Obesity and Heart Failure With Reduced Ejection Fraction
Khan, M. S., Javaid, S. S., Petrie, M. C., Zieroth, S. R., Anker, S. D., & Butler, J. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.02.5083 · Cited by 12
Corrao, S., Scibetta, S., Mirarchi, L., Amodeo, S., Corrao, G., & Calvo, L. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113243 · Cited by 4
Rangraze, I. R., El-Tanani, M. E.-T., Janež, A., Maggio, V., Rabbani, S. A., Jensterle, M., Munda, A., Abbas, E. E., Ali, H. S., Farooqi, M. R., et al. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01868-2 · Cited by 5
“In the pivotal SURMOUNT‑1 trial, mean body weight reduction reached − 20.9% after 72 weeks with tirzepatide 15 mg, and this effect was sustained during its 36‑week open‑label extension phase [2, 3].”
InfluentialMind the Plateau: A Mathematical Modeling Analysis of Long-Term GLP-1 Receptor Agonist Treatment
Hubert, P. A., Coleman, C. D., Grosicki, G. J., Kiel, J., Shepherd, M., Lofton, H. F., Heymsfield, S. B., Thomas, J. G., Dhurandhar, N. V., & Jonnalagadda, S. S. (2026) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2026.156366 · Cited by 6
Seliem, M. A., & Ragab, M. A. (2026) · Nutrition & Metabolism · doi:10.1186/s12986-026-01123-2 · Cited by 8
“Although they are useful in fat loss, clinical trials, including STEP 1 [34] and SURMOUNT-1 [35], suggest that 20–50% of the weight lost is lean body mass, which is a cause of concern in relation to iatrogenic sar-copenia.”
Pulmonary embolism epidemiology: trends, risk factors, comorbidities, and clinical implications
Zuin, M., Becattini, C., Klok, F. A., Bikdeli, B., Barco, S., Farmakis, I. T., Chopard, R., Lang, I. M., Bilato, C., Grandone, E., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag388 · Cited by 6
Beyond weight loss: multisystem benefits of obesity medications
Savas, M., Kuckuck, S., Boon, M. R., & van Rossum, E. F. C. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00100-2 · Cited by 5
Jimenez, L., Múñoz, Ó., Alfonso, D., & Medina, A. M. G. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02118-y · Cited by 15
“Two studies had a risk of bias associated with selective reporting of outcomes [18, 19].”
InfluentialMann, J. P., Lefere, S., Buytaert, M., Alisi, A., Arikan, C., Brecelj, J., Brown, R. M., Degrassi, I., Fiore, G., Fitzpatrick, E., et al. (2026) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/jpn3.70490 · Cited by 10
Tachi, K., Agyei-Nkansah, A. A., Atiase, Y., Forkuo, B., & Agyen-Frimpong, V. A. (2026) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2026-002294 · Cited by 10
Redefining peptide therapeutics with semaglutide
Kruse, T., & Østergaard, S. (2024) · Nature Chemistry · doi:10.1038/s41557-023-01434-4 · Cited by 5
Preservation of healthy lean body mass and function during weight loss
Wilkinson, T. J., Papamargaritis, D., King, J. A., Sargeant, J. A., Sutcliffe, C., Baker, L. A., Taheri, S., Yates, T. E., & Davies, M. J. (2024) · Clinical Obesity · doi:10.1111/cob.12683 · Cited by 4
Polypeptides-Based Nanocarriers in Tumor Therapy
You, J., Guo, Y., & Dong, Z. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16091192 · Cited by 5
Effect of Tirzepatide on Cisplatin and Doxorubicin-Induced Cardiotoxicity and Nephrotoxicity
Alhowail, A. H., Aldubayan, M. A., Ibrahim, T. H., Alharbi, K. S., Almogbel, Y. S., Alhowail, A. H., Almutairi, H. M., Alolayan, S. A., Alharbi, M. S., Alrashidi, A. M., et al. (2025) · International Journal of Pharmacology · doi:10.3923/ijp.2025.47.54 · Cited by 4
Ruggeri, R. M., Grossrubatscher, E. M., Ciocca, E., Hasballa, I., Jaafar, S., Oldani, M., Rubino, M., Russo, F., Isidori, A. M., Colao, A. A. L., et al. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09958-5 · Cited by 5
“These studies did not record any cases of medullary thyroid or pancreatic cancer [112–114].”
Tirzepatide increased force of contraction in the isolated human atrium
Neumann, J., Hofmann, B., Kirchhefer, U., & Gergs, U. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04214-8 · Cited by 4
“Tirzepatide reduced blood glucose levels and led to weight loss in humans, and therefore, tirzepatide was used successfully against obesity in humans (Jastreboff et al. 2022, review: Forzano et al. 2022).”
New Approaches to the Treatment of Severe Obesity—Prehabilitation as the Key to Success
Budny, A., Janczy, A., & Mika, A. (2025) · Current Nutrition Reports · doi:10.1007/s13668-025-00652-1 · Cited by 4
“…h a t o f li r a g l u ti d e a t 2 y e a r s a f t e r r a ndo m i za ti on L e ss ac u t e k i dn e y i n j u r y a nd k i dn e y e v e n t s c o m p a r e d t o G L P - 1 R A [ 132 , 133 ] Another obstacle is the lack of systemic solutions and the inadequate training of healthcare professionals.”
Obesity management before and after pancreas transplantation
Abbasi, A. B., Posselt, A. M., Orandi, B. J., Odorico, J. S., & Stock, P. G. (2025) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000001226 · Cited by 6
Desai, A., Khataniar, H., Tabaku, F., Hashash, J. G., Farraye, F. A., & Kochhar, G. S. (2025) · Indian Journal of Gastroenterology · doi:10.1007/s12664-025-01835-y · Cited by 7
“This dose-response pattern is consistent with findings from the SURMOUNT-1 trial, where TZP at 15 mg once weekly resulted in a mean weight reduction of 20.9% TBW, compared to 19.5% with the 10-mg dose and 15.0% with the 5-mg dose in the obese population [19].”
InfluentialEllberg, C. C., Schwartz, H. R., Witt, A., McCowen, K. C., Fuentes, A. L., & Malhotra, A. (2025) · Current Pulmonology Reports · doi:10.1007/s13665-025-00384-1 · Cited by 6
“Jastreboff et al. have published a number of prominent studies regarding tirzepatide therapy for obesity [44, 45].”
Lu, Y., Liu, Y., Totojani, T., Kim, C., Khera, R., Xu, H., Brush, J. E., Krumholz, H. M., & Abaluck, J. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.26013 · Cited by 8
Safety Choice Drivers of the Coming Treatment Options for Non‐Cirrhotic Metabolic Steatohepatitis
Mangia, A., & Valenti, L. V. C. (2025) · Liver International · doi:10.1111/liv.70271 · Cited by 4
“Based on the striking results of the phase 3 study in obese patients (achieving average weight loss > 20%), it has been approved by the FDA in 2023 after priority review designation for obese patients and in 2024 for sleep apnea patients [60].”
Varghese, J. S., Goldsmith, D. R., Cotes, R. O., Ravikumar, V., Ali, M. K., & Pasquel, F. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01885-4 · Cited by 6
“Expected weight loss was higher among those prescribed tirzepatide, relative to semaglu-tide, consistent with randomized trials that did not include individuals prescribed SGAs [16].”
Ratevosian, J., & Sturchio, J. L. (2025) · BMJ · doi:10.1136/bmj.r1940 · Cited by 4
Liuzzo, G., & Patrono, C. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac384 · Cited by 4
Evidências cientificas sobre o uso de tirzepatida como tratamento da obesidade
Guimarães, B. C. D. S., Zanoteli, H. C., Chaves, R. P., Marcos, C. R. S. A., Aquino, M. E. F. V. D., Rosseto, J. S., Lopes, R. L., Lampert, A. R., & Peroba, G. G. P. D. A. (2022) · Brazilian Journal of Health Review · doi:10.34119/bjhrv5n4-137 · Cited by 15
Combining Metabolic Surgery with Medications for Type 2 Diabetes: Is There a Benefit?
Sudlow, A. C., Pournaras, D. J., & le Roux, C. W. (2022) · Journal of Bariatric Surgery · doi:10.4103/jbs.jbs_16_22 · Cited by 4
Morais, T., Seabra, A. L., Patrício, B. G., Carrageta, D. F., Guimarães, M., Nora, M. C., Oliveira, P. F., Alves, M. G., & Monteiro, M. P. (2023) · Metabolites · doi:10.3390/metabo13050587 · Cited by 5
“The weight loss and glycemic effectiveness attributed to these novel dual agonist molecules have shown they are able to largely surpass the outcomes of previous trials with isolated GLP-1 agonists [33,34].”
BackgroundFrey, S., Ayer, A., Sotin, T., Lorant, V., Louis-Gaubert, C., Arnaud, L., Billon‐Crossouard, S., Croyal, M., Prieur, X., Hadjadj, S., et al. (2023) · Obesity · doi:10.1002/oby.23916 · Cited by 5
“The development of efficient gut hormone-based pharmacotherapy demonstrates their functional relevance of this parameter [27].”
BackgroundMinderis, P., Fokin, A., Povilonis, T., Kvedaras, M., & Ratkevičius, A. (2023) · Nutrients · doi:10.3390/nu15224836 · Cited by 5
“GIP and GLP-1 receptor agonists, which are effective in inducing weight loss, operate by reducing energy intake rather than expenditure [7,8].”
BackgroundThe critical role of abdominal obesity as a crucial cardiovascular risk factor
Corrao, S., Calvo, L., Amico, S., & Argano, C. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15467 · Cited by 4
Metadata
- Authors
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A.
- Affiliations
- Eli Lilly (United States) (US)
- From the Section of Endocrinology and Metabolism, Department of Medicine, and the Section of Pediatric Endocrinology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT (A.M.J.); the Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York (L.J.A.); Eli Lilly, Indianapolis (N.N.A., S.Z., B.L., M.C.B., A.S.); McMaster University, Hamilton, and York University and Wharton Weight Management Clinic, Toronto — all in Ontario, Canada (S.W.); Intend Research, Norman, OK (L.C.); Centro Paulista De Investigação Clínica (Cepic), Sao Paulo (B.A.); and Tokyo-Eki Center-Building Clinic, Tokyo (A.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-21
- Volume
- 387
- Issue
- 3
- Pages
- 205-216
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281934192
- Semantic Scholar
- 3fb03384cc726ebd9d08c76482e6edf35502d0c7
- Cited by
- 3,838
- References
- 28
- Citations by year
- 2026: 1279 · 2025: 1067 · 2024: 776 · 2023: 562 · 2022: 149
- FWCI
- 382.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- tirzepatide, obesity, weight loss, GLP-1 receptor agonists, GIP receptor agonist, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, dose escalation, body mass index, weight-related comorbidities, treatment discontinuation, treatment-emergent adverse events, drug safety, subcutaneous administration
- MeSH terms
- Tirzepatide, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.